Skip to main content
Premium Trial:

Request an Annual Quote

Lynx, Wilex Will Study Gene Expression Changes With New Cancer Drug

NEW YORK, April 23-Lynx Therapeutics and Wilex AG will work together to identify genes regulated by Wilex' lead compound for renal cell carcinoma, the companies said today.


Lynx will use its Massively Parallel Signature Sequencing system to analyze gene expression differences in samples treated with the Wilex compound.


Wilex CEO Olaf Wilhelm said in a statement that the Lynx technology may reveal markers that can predict patient response to drug therapy, making it possible to identify those patient subpopulations most likely to benefit from the new drug. The process may also reveal additional therapeutic targets for combination drug treatment.


Lynx will receive service payments from Wilex.


The Wilex compound, WX-G250, is designed to induce antibody dependent cellular cytoxicity in renal cell carcinomas. It is currently in phase II clinical trials.


Renal cell carcinoma is the tenth most common cancer in the Unites States, and causes more than 12,000 deaths annually.


Wilex, a biopharmaceutical company based in Munich, focuses on treatments for cancer.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.